In last trading session, Myriad Genetics, Inc (NASDAQ:MYGN) saw 0.36 million shares changing hands with its beta currently measuring 1.89. Company’s recent per share price level of $16.58 trading at $0.3 or 1.84% at ring of the bell on the day assigns it a market valuation of $1.51B. That closing price of MYGN’s stock is at a discount of -76.72% from its 52-week high price of $29.30 and is indicating a premium of 11.22% from its 52-week low price of $14.72. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.97 million shares which gives us an average trading volume of 816.54K if we extend that period to 3-months.

For Myriad Genetics, Inc (MYGN), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 2.60. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 5 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.03 in the current quarter.

Myriad Genetics, Inc (NASDAQ:MYGN) trade information

Upright in the green during last session for gaining 1.84%, in the last five days MYGN remained trading in the green while hitting it’s week-highest on Wednesday, 11/27/24 when the stock touched $16.58 price level, subtracting -0.3% to its value on the day. Myriad Genetics, Inc’s shares saw a change of -13.38% in year-to-date performance and have moved 9.66% in past 5-day. Myriad Genetics, Inc (NASDAQ:MYGN) showed a performance of -27.18% in past 30-days. Number of shares sold short was 3.69 million shares which calculate 3.96 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 29 to the stock, which implies a rise of 42.83% to its current value. Analysts have been projecting 22 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -32.69% in reaching the projected high whereas dropping to the targeted low would mean a loss of -32.69% for stock’s current value.

Myriad Genetics, Inc (MYGN) estimates and forecasts

Statistics highlight that Myriad Genetics, Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -27.15% of value to its shares in past 6 months, showing an annual growth rate of 144.44% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 11.62% from the last financial year’s standing.

13 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 213.56M for the same. And 11 analysts are in estimates of company making revenue of 213.44M in the next quarter. Company posted 196.6M and 202.2M of sales in current and next quarters respectively a year earlier.

In 2024, company’s earnings growth rate is likely to be around 147.62% while estimates for its earnings growth in next 5 years are of 70.00%.

Myriad Genetics, Inc (NASDAQ:MYGN)’s Major holders

Insiders are in possession of 2.02% of company’s total shares while institution are holding 102.19 percent of that, with stock having share float percentage of 104.30%. Investors also watch the number of corporate investors in a company very closely, which is 102.19% institutions for Myriad Genetics, Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at MYGN for having 15.15 million shares of worth $370.59 million. And as of 2024-06-30, it was holding 18.5369 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 10.06 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.314 of outstanding shares, having a total worth of $246.18 million.

On the other hand, iShares Core S&P Smallcap ETF and Vanguard Explorer Fund, Inc. are the top two Mutual Funds which own company’s shares. As of Aug 31, 2024 , the former fund manager was holding 6.09 shares of worth $99.02 million or 6.69% of the total outstanding shares. The later fund manager was in possession of 3.48 shares on Jul 31, 2024 , making its stake of worth around $56.63 million in the company or a holder of 3.82% of company’s stock.